Indian technical body suggests major fine-tuning of trial compensation norms
This article was originally published in SRA
Executive Summary
India's Drug Technical Advisory Board (DTAB), the highest technical body under the country's Drugs and Cosmetics Act, has recommended significant changes and even the withdrawal of certain controversial clauses in the country's recently notified clinical trial compensation norms1-3.